BRPI0807547A2 - Inibidores de aspartil protease hetercíclicos - Google Patents

Inibidores de aspartil protease hetercíclicos

Info

Publication number
BRPI0807547A2
BRPI0807547A2 BRPI0807547-6A2A BRPI0807547A BRPI0807547A2 BR PI0807547 A2 BRPI0807547 A2 BR PI0807547A2 BR PI0807547 A BRPI0807547 A BR PI0807547A BR PI0807547 A2 BRPI0807547 A2 BR PI0807547A2
Authority
BR
Brazil
Prior art keywords
hypercyclic
aspartil
protease inhibitors
protease
inhibitors
Prior art date
Application number
BRPI0807547-6A2A
Other languages
English (en)
Inventor
Zhaoning Zhu
Corey Strickland
Elizabeth M Smith
Andrew Stamford
William J Greenlee
Robert D Mazzola
John Caldwell
Jared N Cumming
Lingyan Wang
Yusheng Wu
Ulrich Iserloh
Xiaoxiang Liu
Ying Huang
Guoqing Li
Jianping Pan
Jeffrey A Misiaszek
Tao Guo
Thuy X H Le
Kurt W Saionz
Gaifa Lai
Jingqi Duo
Chuanxing Qu
Yuefei Shao
Suresh D Babu
Rachael C Hunter
Michelle L Morris
Huizhong Gu
Gang Qian
Dawit Tadesse
Original Assignee
Schering Corp
Corey Strickland
Elizabeth M Smith
Andrew Stamford
William J Greenlee
Robert D Mazzola Jr
John Caldwell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39511364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0807547(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Corey Strickland, Elizabeth M Smith, Andrew Stamford, William J Greenlee, Robert D Mazzola Jr, John Caldwell filed Critical Schering Corp
Publication of BRPI0807547A2 publication Critical patent/BRPI0807547A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Gas Separation By Absorption (AREA)
  • Electroluminescent Light Sources (AREA)
BRPI0807547-6A2A 2007-02-23 2008-02-20 Inibidores de aspartil protease hetercíclicos BRPI0807547A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/710,582 US7763609B2 (en) 2003-12-15 2007-02-23 Heterocyclic aspartyl protease inhibitors
PCT/US2008/002182 WO2008103351A2 (en) 2007-02-23 2008-02-20 Heterocyclic aspartyl protease inhibitors

Publications (1)

Publication Number Publication Date
BRPI0807547A2 true BRPI0807547A2 (pt) 2014-06-17

Family

ID=39511364

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807547-6A2A BRPI0807547A2 (pt) 2007-02-23 2008-02-20 Inibidores de aspartil protease hetercíclicos

Country Status (33)

Country Link
US (5) US7763609B2 (pt)
EP (1) EP2097387B1 (pt)
JP (2) JP5340177B2 (pt)
KR (1) KR101612961B1 (pt)
CN (1) CN101715442B (pt)
AR (2) AR065421A1 (pt)
AU (1) AU2008219071B2 (pt)
BR (1) BRPI0807547A2 (pt)
CA (1) CA2678958C (pt)
CL (1) CL2008000531A1 (pt)
CO (1) CO6220968A2 (pt)
CY (1) CY1117946T1 (pt)
DK (1) DK2097387T3 (pt)
EC (1) ECSP099597A (pt)
ES (1) ES2582367T3 (pt)
HR (1) HRP20160876T1 (pt)
HU (1) HUE029867T2 (pt)
IL (1) IL200561A (pt)
LT (1) LT2097387T (pt)
ME (1) ME02528B (pt)
MX (1) MX2009009063A (pt)
MY (1) MY149183A (pt)
NZ (1) NZ579301A (pt)
PE (2) PE20081884A1 (pt)
PL (1) PL2097387T3 (pt)
PT (1) PT2097387T (pt)
RS (1) RS54979B1 (pt)
RU (1) RU2496774C2 (pt)
SG (1) SG179407A1 (pt)
SI (1) SI2097387T1 (pt)
TW (2) TWI355937B (pt)
WO (1) WO2008103351A2 (pt)
ZA (1) ZA200905837B (pt)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3259012B2 (ja) 1995-08-02 2002-02-18 ミヤチテクノス株式会社 インバータ式抵抗溶接制御装置
JP3259013B2 (ja) 1995-08-10 2002-02-18 ミヤチテクノス株式会社 インバータ式抵抗溶接電源装置
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1896032B1 (en) 2005-06-14 2012-10-31 Merck Sharp & Dohme Corp. The preparation and use of compounds as protease inhibitors
AU2006259574A1 (en) * 2005-06-14 2006-12-28 Schering Corporation The preparation and use of compounds as aspartyl protease inhibitors
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
ATE482214T1 (de) * 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
CN101346357B (zh) 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
JP2009520027A (ja) * 2005-12-19 2009-05-21 ワイス ２−アミノ−５−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用
US8168641B2 (en) 2006-06-12 2012-05-01 Schering Corporation Aspartyl protease inhibitors
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
CN101631779A (zh) * 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
JP5383483B2 (ja) * 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
EP2689780A1 (en) 2007-04-24 2014-01-29 Shionogi & Co., Ltd. Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
EP2586311B1 (de) 2008-07-17 2016-12-14 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
EP2324032B1 (en) 2008-08-19 2014-10-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8426447B2 (en) * 2008-09-11 2013-04-23 Amgen Inc. Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use
CN102186841A (zh) * 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
DE102008063992A1 (de) * 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
WO2010080864A1 (en) * 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
EA020875B1 (ru) 2009-03-13 2015-02-27 Вайтаи Фармасьютиклз, Инк. Ингибиторы бета-секретазы
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2485920B1 (en) * 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) * 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
KR20120104570A (ko) 2009-12-11 2012-09-21 시오노기세야쿠 가부시키가이샤 옥사진 유도체
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
JP5584352B2 (ja) 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
US8883782B2 (en) 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
RU2013150349A (ru) 2011-04-13 2015-05-20 Мерк Шарп И Доум Корп. 5-замещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов васе, содержащие их композиции и их применение
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
JP2014526560A (ja) 2011-09-21 2014-10-06 アムジエン・インコーポレーテツド β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
WO2013142396A1 (en) * 2012-03-23 2013-09-26 Merck Sharp & Dohme Corp. N3-substituted iminopyrimidinones as renin inhibitors, compositions, and their use
EP2669286A1 (en) * 2012-05-31 2013-12-04 Ares Trading S.A. Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
EP2900650A1 (en) 2012-09-28 2015-08-05 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EP2908824B1 (en) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
US9353072B2 (en) * 2012-10-31 2016-05-31 Purdue Research Foundation Antimicrobial substituted thiazoles and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP2931284B1 (en) * 2012-12-14 2017-08-23 Merck Sharp & Dohme Corp. Bace inhibitors of iminothiadiazine dioxides
AU2013363151A1 (en) 2012-12-20 2015-06-04 Merck Sharp & Dohme Corp. C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors
US9489013B2 (en) 2012-12-20 2016-11-08 Merck Sharp & Dohme Corp. C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use
WO2014099788A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. C5-spiro iminothiadiazine dioxides as bace inhibitors
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
WO2014127881A1 (de) 2013-02-25 2014-08-28 Merck Patent Gmbh 2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
JP6389830B2 (ja) 2013-03-01 2018-09-12 アムジエン・インコーポレーテツド ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
US9353089B2 (en) * 2013-03-26 2016-05-31 Saint Louis University Compositions and methods for the treatment of malaria
WO2015038446A1 (en) 2013-09-13 2015-03-19 Merck Sharp & Dohme Corp. C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use
US9745324B2 (en) 2013-12-18 2017-08-29 Merck Sharp & Dohme Corp. Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use
WO2015094930A1 (en) 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. C-6 spirocarbocyclic iminothiadiazine dioxides as bace inhibitors, compositions, and their use
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
EP3191447B1 (en) 2014-09-12 2019-05-01 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
US9868738B2 (en) 2014-09-19 2018-01-16 Merck Sharp & Dohme Corp. Diazine-fused amidines as BACE inhibitors, compositions, and their use
US10047098B2 (en) 2014-11-25 2018-08-14 Merck Sharp & Dohme Corp. C5-C6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use
WO2016118404A1 (en) 2015-01-20 2016-07-28 Merck Sharp & Dohme Corp. Iminothiadiazine dioxides bearing an amine-linked substituent as bace inhibitors, compositions, and their use
CA2979905A1 (en) * 2015-04-21 2016-10-27 Allgenesis Biotherapeutics, Inc. Compounds and their use as bace1 inhibitors
WO2017061534A1 (en) 2015-10-08 2017-04-13 Shionogi & Co., Ltd. Dihydrothiazine derivatives
EP3380464B1 (en) * 2015-11-25 2020-05-27 UCB Biopharma SRL Iminotetrahydropyrimidinone derivatives as plasmepsin v inhibitors
WO2017095759A1 (en) 2015-12-04 2017-06-08 Merck Sharp & Dohme Corp. C5-c6-carbocyclic fused iminothiadiazine dioxides as bace inhibitors, compositions, and their use
US10604534B2 (en) 2016-02-11 2020-03-31 Merck Sharp & Dohme Corp. C5-C6-oxacyclic fused iminothiadiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use
EP3414253B1 (en) 2016-02-11 2021-07-21 Merck Sharp & Dohme Corp. C5-c6-oxacylic fused iminothiazine dioxide compounds bearing an ether linker as bace inhibitors, compositions, and their use
WO2017142825A2 (en) * 2016-02-18 2017-08-24 Merck Sharp & Dohme Corp. N3-substituted iminopyrimidinones as antimalarial agents
US20190046507A1 (en) * 2016-02-18 2019-02-14 Merck Sharp & Dohme Corp. Compounds for the treatment of malaria
GB201603104D0 (en) * 2016-02-23 2016-04-06 Ucb Biopharma Sprl Therapeutic agents
EP3428150B1 (en) * 2016-03-11 2023-07-12 Takeda Pharmaceutical Company Limited Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
ES2938615T3 (es) 2016-08-15 2023-04-13 Bayer Cropscience Ag Derivados del heterociclo bicíclico condensado como agentes de control de plagas
JP7471818B2 (ja) 2016-08-18 2024-04-22 ヴィダック ファーマ リミテッド ピペラジン誘導体、医薬組成物、及びその使用方法
EP3551192A4 (en) 2016-12-06 2020-07-08 Merck Sharp & Dohme Corp. HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS
EP3558285A4 (en) * 2016-12-22 2020-09-09 Merck Sharp & Dohme Corp. USEFUL HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS
US20200069691A1 (en) * 2016-12-22 2020-03-05 Merck Sharp & Dohme Corp. Heterocyclic compounds as hiv protease inhibitors
CN106810458B (zh) * 2016-12-31 2019-05-03 武汉工程大学 一种拆分dl-2-氨基丙醇制备l-2-氨基丙醇的方法
JOP20180092A1 (ar) * 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
GB201805816D0 (en) 2018-04-06 2018-05-23 Ucb Biopharma Sprl Therapeutic agents
CA3098430A1 (en) 2018-04-27 2019-10-31 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity
US10844044B2 (en) * 2018-06-14 2020-11-24 Vanderbilt University WDR5 inhibitors and modulators
US10933020B2 (en) 2018-09-28 2021-03-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
TW202104210A (zh) * 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
GB201906804D0 (en) 2019-05-14 2019-06-26 Ucb Biopharma Sprl Therapeutic agents
CN110066221B (zh) * 2019-05-16 2022-03-08 海门瑞一医药科技有限公司 一种环丙基甲胺的制备方法
CN110256285B (zh) * 2019-07-09 2022-03-18 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种稳定同位素标记拟除虫菊酯的合成方法
WO2021026884A1 (en) * 2019-08-15 2021-02-18 Merck Sharp & Dohme Corp. Antimalarial agents
EP4017591A1 (en) 2019-08-19 2022-06-29 UCB Biopharma SRL Antimalarial hexahydropyrimidine analogues
WO2021097676A1 (en) * 2019-11-19 2021-05-27 Merck Sharp & Dohme Corp. Antimalarial agents
WO2021155612A1 (en) * 2020-02-09 2021-08-12 Merck Sharp & Dohme Corp. Antimalarial agents
GB202010606D0 (en) 2020-07-10 2020-08-26 Ucb Biopharma Sprl Therapeutic agents
WO2023102747A1 (en) * 2021-12-07 2023-06-15 Merck Sharp & Dohme Llc Antimalarial agents
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
JP2025505665A (ja) 2022-02-08 2025-02-28 ユーシービー バイオファルマ エスアールエル 抗マラリア性ヘキサヒドロピリミジン類似体

Family Cites Families (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200123A (en) 1962-01-26 1965-08-10 Richardson Merreil Inc Imidazoquinolines
US3197476A (en) 1962-12-06 1965-07-27 Air Prod & Chem Method of synthesis of 1-acyl imidazoles
US3632814A (en) 1968-11-25 1972-01-04 Velsicol Chemical Corp Phosphoramidate esters
ZA87563B (en) 1986-02-03 1987-09-30 Squibb & Sons Inc N-heterocyclic alcohol renin inhibitors
DE3643890A1 (de) 1986-12-22 1988-06-30 Basf Ag Neue polyalkylpiperidinderivate mit alkylenbruecken, ihre verwendung als stabilisator und zwischenprodukte
WO1989003842A1 (en) 1987-10-21 1989-05-05 The Upjohn Company Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety
EP0361341A3 (en) 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
GB9109972D0 (en) 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
WO1993013064A1 (fr) 1991-12-26 1993-07-08 Nippon Soda Co., Ltd. Procede de production d'un derive d'azetidinone substitue en position 4
US5731431A (en) 1991-12-26 1998-03-24 Nippon Soda Co., Ltd. Process for preparing 4-substituted azetidinone derivatives
ATE195530T1 (de) 1992-05-20 2000-09-15 Merck & Co Inc 17-ether und thioether von 4-aza-steroiden
CA2135173A1 (en) 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
DE4233715A1 (de) 1992-10-07 1994-04-14 Bayer Ag Substituierte Carbamoylpyrazoline
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
US5502222A (en) 1994-06-01 1996-03-26 Schering Corporation Process for preparing delta 9,11 and 21-chloro corticosteroids
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
JPH11509846A (ja) 1995-07-31 1999-08-31 ノボ ノルディスク アクティーゼルスカブ ヘテロ環式化合物、それらの調製及び使用
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
GB9611046D0 (en) 1996-05-25 1996-07-31 Wivenhoe Techn Ltd Pharmacological compounds
US5935958A (en) 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
GB9615831D0 (en) 1996-07-27 1996-09-11 Agrevo Uk Ltd Fungicides
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US5981556A (en) 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
JPH11335518A (ja) 1998-03-25 1999-12-07 Polyplastics Co ポリアセタ―ル樹脂組成物およびその製造方法
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6413725B1 (en) * 1998-08-07 2002-07-02 California Institute Of Technology Biochemical assay to monitor the ubiquitin ligase activities of cullins
US6864240B1 (en) 1999-06-15 2005-03-08 Elan Pharmaceuticals, Inc. Dipeptide inhibitors of β-secretase
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
WO2001044239A2 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AU2001252958A1 (en) 2000-03-23 2001-10-03 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
AU2001253090A1 (en) 2000-04-03 2001-10-15 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of abeta protein production
US6632812B2 (en) 2000-04-11 2003-10-14 Dupont Pharmaceuticals Company Substituted lactams as inhibitors of Aβ protein production
US6713276B2 (en) 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
DE60116313T2 (de) 2000-06-30 2006-08-31 Elan Pharmaceuticals, Inc., San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
AU2001273429A1 (en) 2000-07-14 2002-01-30 Vigilant Networks Llc Single ended attenuation measurement
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
US6414161B1 (en) 2000-08-09 2002-07-02 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis of (R)-3-(4-Bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-H-imidazo[1,2-a]imidazol-2-one
US6458812B1 (en) 2000-12-22 2002-10-01 Schering Corporation Muscarinic antagonists
WO2002062803A1 (en) 2001-02-08 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Thienopyrimidine derivative
AU2002306734A1 (en) 2001-03-15 2002-10-03 The Johns Hopkins University Inhibitors of plasmepsins
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
MXPA03011046A (es) 2001-06-01 2004-06-25 Elan Pharm Inc Hidroxialquilaminas.
US20070213407A1 (en) 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
BR0213139A (pt) 2001-10-04 2004-08-10 Elan Pharm Inc Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
ES2269774T3 (es) 2001-10-10 2007-04-01 Schering Corporation Compuestos de piperidina como antagonistas muscarinicos.
US6673821B2 (en) 2001-10-22 2004-01-06 Enanta Pharmaceuticals, Inc. Nitrogen heterocycle inhibitors of aspartyl protease
AU2002359301B2 (en) 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
EP1453789A2 (en) 2001-11-08 2004-09-08 Elan Pharmaceuticals, Inc. N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
OA12812A (en) 2001-11-19 2006-07-10 Elan Pharm Inc (4-phenyl) Piperidin-3-yl-phenylcarboxylate derovatoves and related compounds as beta-secretase inhibitors for the treatment of Alzheimer's Disease.
AU2002360508A1 (en) 2001-12-06 2003-06-23 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
GEP20063920B (en) 2001-12-20 2006-09-11 Bristol Myers Squibb Co Alpha-(n-sulphonamido) acetamide derivatives as beta-amyloid inhibitors
EP1572904B1 (en) 2002-02-21 2009-04-15 Pharmacia & Upjohn Company LLC Modified bace
EP1515944A1 (en) 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
WO2004002478A1 (en) 2002-06-27 2004-01-08 Elan Pharmaceuticals, Inc. Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
CA2497979A1 (en) 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
UY27967A1 (es) 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
EP1551809A1 (en) 2002-10-09 2005-07-13 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
WO2004042026A2 (en) 2002-11-04 2004-05-21 Florida State University Research Foundation NUCLEIC ACID AND ALLERGENIC POLYPEPTIDES ENCODED THEREBY IN CASHEW NUTS (Anacardium occidentale)
ATE443043T1 (de) 2002-11-12 2009-10-15 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2004050609A1 (en) 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
WO2004076478A1 (ja) 2003-02-28 2004-09-10 Yoshiaki Kiso βセクレターゼ阻害活性を有するペプチド誘導体
CA2523232A1 (en) 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer's disease
GB0309221D0 (en) 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
MXPA05012196A (es) 2003-05-12 2006-02-08 Pfizer Prod Inc Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
GB0314302D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Novel compounds
AU2004255183A1 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
DE10336035A1 (de) 2003-08-01 2005-03-24 Endress + Hauser Wetzer Gmbh + Co Kg Verfahren zur automatischen Anpassung eines busfähigen Feldgerätes der Prozessautomatisierungstechnik an das auf dem Feldbus verwendete Busprotokoll
ATE424383T1 (de) 2003-08-08 2009-03-15 Schering Corp Cyclische amine mit benzamidsubstituent als bace- 1-inhibitoren
US7598250B2 (en) 2003-08-08 2009-10-06 Schering Corporation Cyclic amine BACE-1 inhibitors having a heterocyclic substituent
BRPI0413709A (pt) 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
WO2005042472A2 (en) 2003-10-30 2005-05-12 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
US20050171112A1 (en) 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20060034848A1 (en) 2003-11-07 2006-02-16 Ayae Kinoshita Methods and compositions for treating Alzheimer's disease
KR101225311B1 (ko) 2003-11-21 2013-01-22 비쥬얼 피직스 엘엘씨 마이크로-광학 보안 및 화상 연출 시스템
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
SG163508A1 (en) * 2003-12-15 2010-08-30 Schering Corp Heterocyclic aspartyl protease inhibitors
JP2007517781A (ja) 2003-12-19 2007-07-05 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病治療用のフェニルアミドおよびピリジルアミド系β−セクレターゼ阻害薬
US7205370B2 (en) * 2004-01-12 2007-04-17 Bridgestone Corporation Polymeric nano-particles of flower-like structure and applications
WO2005070407A1 (en) 2004-01-21 2005-08-04 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
JP2007528404A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換された尿素およびカルバメート、フェナシル−２−ヒドロキシ−３−ジアミノアルカン、ならびにベンズアミド−２−ヒドロキシ−３−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
WO2005097767A1 (en) 2004-03-30 2005-10-20 Merck & Co., Inc. 2-aminothiazole compounds useful as aspartyl protease inhibitors
US7232820B2 (en) 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
EP1740581B1 (en) 2004-04-20 2012-08-22 Merck Sharp & Dohme Corp. 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
CA2563615A1 (en) 2004-04-20 2005-11-03 Merck & Co., Inc. 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
EP1740573A1 (en) 2004-04-22 2007-01-10 Eli Lilly And Company Amides as bace inhibitors
US7585885B2 (en) 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
US7449599B2 (en) 2004-05-13 2008-11-11 Merck + Co Inc. Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005113582A1 (en) 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
AR049300A1 (es) 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
JP2008502684A (ja) 2004-06-15 2008-01-31 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病を治療するためのベータ−セクレターゼ阻害剤として有用なピロリジン−３−イル化合物
ATE444962T1 (de) 2004-06-16 2009-10-15 Wyeth Corp Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung
JP2008503460A (ja) 2004-06-16 2008-02-07 ワイス β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
DE602005025363D1 (de) 2004-07-22 2011-01-27 Schering Corp Substituierte amide als inhibitoren der beta-sekretase
ATE396990T1 (de) 2004-07-28 2008-06-15 Schering Corp Makrocyclische inhibitoren der beta-sekretase
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
PT1789398E (pt) 2004-08-06 2010-10-21 Janssen Pharmaceutica Nv Derivados de 2-amino- quinazolina úteis como inibidores de β-secretase (bace)
JP5046932B2 (ja) 2004-08-06 2012-10-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ β−セクレターゼ（ＢＡＣＥ）のインヒビターとして有用な新規の２−アミノ−キナゾリン誘導体
WO2006018287A1 (en) 2004-08-17 2006-02-23 Novartis Ag Three-dimensional strcture of the human aspartyl protease beta-site amyloid precursor-protein-cleaving enzyme 2 (bace2), methods and use thereof
US7388007B2 (en) 2004-08-26 2008-06-17 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
CA2576782A1 (en) 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using substituted ethanolcyclicamine aspartyl protease inhibitors
WO2006029850A1 (en) 2004-09-14 2006-03-23 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
AU2005286844A1 (en) 2004-09-17 2006-03-30 Comentis, Inc Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
SV2006002232A (es) 2004-09-21 2006-05-25 Lilly Co Eli Inhibidores bace ref. x-16940
WO2006044497A2 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
GB0422766D0 (en) 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422755D0 (en) 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422765D0 (en) 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2006041405A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
EP1802587A4 (en) 2004-10-15 2010-02-17 Astrazeneca Ab SUBSTITUTED AMINO BINDINGS AND THEIR APPLICATIONS
AU2005310239A1 (en) 2004-10-29 2006-06-08 Merck & Co., Inc. 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2006050862A1 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
ATE512147T1 (de) 2004-11-23 2011-06-15 Merck Sharp & Dohme Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
ES2259891B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
WO2006066172A1 (en) * 2004-12-17 2006-06-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
GB0500683D0 (en) 2005-01-13 2005-02-23 Novartis Ag Organic compounds
EP2264036A1 (en) 2005-01-14 2010-12-22 Wyeth LLC (Formerly Known As Wyeth) Amino-imidazolones for the inhibition of beta-secretase
DE602006021535D1 (de) 2005-01-19 2011-06-09 Merck Sharp & Dohme Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
CN101106994A (zh) 2005-01-19 2008-01-16 默克公司 用于治疗阿尔茨海默氏病的氨基甲基β-分泌酶抑制剂
WO2006081072A1 (en) 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
US20070299093A1 (en) 2005-01-27 2007-12-27 Alma Mater Studiorum-Universitá Di Bologna Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation
AU2006209079A1 (en) 2005-01-27 2006-08-03 Alma Mater Studiorum-Universita' Di Bologna Organic compounds useful for the treatment of Alzheimer's disease, their use and method of preparation
BRPI0607094A2 (pt) 2005-02-01 2009-08-04 Wyeth Corp composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica
CN101146769A (zh) 2005-02-14 2008-03-19 惠氏公司 作为β-分泌酶抑制剂的唑基酰基胍
WO2006088705A1 (en) 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
WO2006088694A1 (en) 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
US7745470B2 (en) 2005-03-10 2010-06-29 Bristol-Myers Squibb Company Isophthalates as beta-secretase inhibitors
JP2008535863A (ja) 2005-04-08 2008-09-04 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害する化合物およびその使用方法
WO2006133588A1 (en) 2005-06-13 2006-12-21 Oncalis Ag ARYL UREA COMPOUNDS AS β-SECRETASE INHIBITORS
US7759353B2 (en) 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
EP1896032B1 (en) 2005-06-14 2012-10-31 Merck Sharp & Dohme Corp. The preparation and use of compounds as protease inhibitors
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
AU2006259574A1 (en) 2005-06-14 2006-12-28 Schering Corporation The preparation and use of compounds as aspartyl protease inhibitors
EP1896406A2 (en) 2005-06-14 2008-03-12 Shering Corporation The preparation and use of compounds as protease inhibitors
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
ATE482214T1 (de) 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
US7612069B2 (en) 2005-06-21 2009-11-03 Bristol-Myers Squibb Company Acyl guanidines as beta-secretase inhibitors
US7273882B2 (en) 2005-06-21 2007-09-25 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as β-secretase inhibitors
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
JP2009500329A (ja) 2005-06-30 2009-01-08 ワイス アミノ−５−（６員）ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用
WO2007011810A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
CA2618474A1 (en) 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
JP2009504614A (ja) 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
JP2009504612A (ja) 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
US20100298278A1 (en) 2005-08-11 2010-11-25 Christian Eickmeier Inhibitors of beta-secretase for the treatment of alzheimer's disease
WO2007021793A1 (en) 2005-08-12 2007-02-22 Bristol-Myers Squibb Company Macrocyclic diaminopropanes as beta-secretase inhibitors
US7601751B2 (en) 2005-09-01 2009-10-13 Bristol-Myers Squibb Company Indole acetic acid acyl guanidines as β-secretase inhibitors
AU2006294620A1 (en) 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
JP2009511589A (ja) 2005-10-12 2009-03-19 エラン ファーマシューティカルズ，インコーポレイテッド アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
CN101346357B (zh) 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
WO2007050612A1 (en) 2005-10-25 2007-05-03 Janssen Pharmaceutica N.V. 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (bace)
ATE478070T1 (de) 2005-10-27 2010-09-15 Schering Corp Heterozyklische aspartyl-proteasehemmer
EP1943246A1 (en) 2005-10-31 2008-07-16 Schering Corporation Aspartyl protease inhibitors
WO2007051333A1 (en) 2005-11-02 2007-05-10 Oncalis Ag Triazine beta-secretase inhibitors
CN101360720A (zh) 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶酮衍生物及其用途
CN101360722A (zh) 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶衍生物及其用途
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
EP1951682A4 (en) 2005-11-15 2011-06-15 Astrazeneca Ab NEW 2-AMINOPYRIMIDONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
JP5274258B2 (ja) 2005-11-21 2013-08-28 アムジエン・インコーポレーテツド β−セクレターゼ調節物質及び使用方法
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
CN101360716A (zh) 2005-11-21 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途
WO2007060526A1 (en) 2005-11-22 2007-05-31 Pfizer Products Inc. Substituted azacycloalkanes useful for treating cns conditions
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
AR058381A1 (es) 2005-12-19 2008-01-30 Astrazeneca Ab Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
JP2009520027A (ja) 2005-12-19 2009-05-21 ワイス ２−アミノ−５−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用
GB0526614D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
EP1816122A3 (en) 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
WO2007092854A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US7932261B2 (en) 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7776882B2 (en) 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
GB0602951D0 (en) 2006-02-14 2006-03-29 Novartis Ag Organic Compounds
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US7408071B2 (en) 2006-04-03 2008-08-05 Bristol-Myers Squibb Company N-aryl pyrrolidine derivatives as beta-secretase inhibitors
US7390925B2 (en) 2006-04-03 2008-06-24 Bristol-Myers Squibb Company Oxime-containing acyl guanidines as beta-secretase inhibitors
US20070232624A1 (en) * 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
CN101460480A (zh) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
CA2649396A1 (en) 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US8168641B2 (en) * 2006-06-12 2012-05-01 Schering Corporation Aspartyl protease inhibitors
US20080051420A1 (en) 2006-06-14 2008-02-28 Astrazeneca Ab New Compounds 317
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
CA2656869A1 (en) 2006-07-20 2008-01-24 Novartis Ag Macrocyclic lactams
TW200817406A (en) 2006-08-17 2008-04-16 Wyeth Corp Imidazole amines as inhibitors of β-secretase
US7700606B2 (en) 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
MX2009003102A (es) 2006-09-21 2009-04-01 Wyeth Corp INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA.
JP2010505833A (ja) 2006-10-06 2010-02-25 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのマクロ環式スピロピペリジンβ−セクレターゼ阻害剤
WO2008063114A1 (en) 2006-11-20 2008-05-29 Astrazeneca Ab Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
CN101631779A (zh) 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
CN101209976B (zh) 2006-12-29 2012-01-11 中国人民解放军军事医学科学院毒物药物研究所 取代的酒石酸衍生物及其用于制备β-分泌酶抑制剂的用途
JP2010515681A (ja) 2007-01-04 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション アルツハイマー病治療用の二環式スピロピペリジンベータ−セクレターゼ阻害剤
MX2009008255A (es) 2007-02-02 2009-08-12 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos taar1.
CL2008000784A1 (es) 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
PE20090617A1 (es) 2007-03-23 2009-05-08 Wyeth Corp Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
NZ580671A (en) 2007-04-16 2012-03-30 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
EP2689780A1 (en) 2007-04-24 2014-01-29 Shionogi & Co., Ltd. Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009005470A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005471A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009007300A2 (en) 2007-07-06 2009-01-15 Boehringer Ingelheim International Gmbh Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
WO2009013293A1 (en) 2007-07-24 2009-01-29 Novartis Ag Substituted cyclohexanecarboxamides useful as bace inhibitors
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
CL2009000119A1 (es) 2008-01-22 2010-03-05 Boehringer Ingelheim Int Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
CA2713998A1 (en) 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace)
CN101970429B (zh) 2008-01-29 2013-05-29 詹森药业有限公司 可用作β-分泌酶(BACE)抑制剂的2-氨基喹啉衍生物
KR101259240B1 (ko) 2008-02-18 2013-04-29 시에나 바이오테크 에스.피.에이. 4,5-다이하이드로-옥사졸-2-일 아민 유도체
US8492387B2 (en) 2008-02-28 2013-07-23 Merck, Sharp & Dohme, Corp. 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
CA2721786A1 (en) 2008-05-05 2009-11-12 Pfizer Inc. Novel class of spiro piperidines for the treatment of neurodegenerative diseases
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
WO2010013794A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
US8426447B2 (en) 2008-09-11 2013-04-23 Amgen Inc. Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use
WO2010038686A1 (ja) 2008-09-30 2010-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規な縮合アミノジヒドロチアジン誘導体
WO2010042030A1 (en) 2008-10-07 2010-04-15 Medivir Ab Aspartyl protease inhibitors
EP2349244A4 (en) 2008-10-10 2012-09-19 Comentis Inc BICYCLIC COMPOUNDS FOR INHIBITING BETA SEKRETASE ACTIVITY AND METHOD OF USE THEREOF
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
US20100125081A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574
EP2376083A4 (en) 2008-11-20 2012-06-20 Purdue Research Foundation QUINAZOLIN-BASED BACE-1 INHIBITORS AND METHODS OF USE
AU2010241929A1 (en) 2009-04-27 2011-10-06 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
EP2424533A4 (en) 2009-04-27 2012-10-17 High Point Pharmaceuticals Llc SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
EP2486006A4 (en) 2009-10-05 2013-05-01 Comentis Inc SULPHONAMID-PYRROLIDIN COMPOUNDS FOR INHIBITING BETA SEKRETASE ACTIVITY AND METHOD OF USE THEREOF
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
KR20120104570A (ko) 2009-12-11 2012-09-21 시오노기세야쿠 가부시키가이샤 옥사진 유도체
EP2518059A4 (en) 2009-12-24 2013-05-29 Shionogi & Co 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE
JP5584352B2 (ja) 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
US8883782B2 (en) 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use

Also Published As

Publication number Publication date
JP2010519254A (ja) 2010-06-03
WO2008103351A3 (en) 2009-07-23
NZ579301A (en) 2012-05-25
US20080200445A1 (en) 2008-08-21
EP2097387A2 (en) 2009-09-09
DK2097387T3 (en) 2016-08-15
AR065421A1 (es) 2009-06-03
US20120231017A1 (en) 2012-09-13
CN101715442A (zh) 2010-05-26
PL2097387T3 (pl) 2016-11-30
US20120231018A1 (en) 2012-09-13
JP2013014628A (ja) 2013-01-24
AU2008219071A2 (en) 2010-11-25
CA2678958C (en) 2014-10-14
JP5340177B2 (ja) 2013-11-13
US8691831B2 (en) 2014-04-08
HRP20160876T1 (hr) 2016-09-23
SG179407A1 (en) 2012-04-27
TW201139415A (en) 2011-11-16
MX2009009063A (es) 2010-01-29
LT2097387T (lt) 2016-10-10
WO2008103351A2 (en) 2008-08-28
CL2008000531A1 (es) 2008-09-22
RS54979B1 (sr) 2016-11-30
PT2097387T (pt) 2016-07-20
HK1130792A1 (zh) 2010-01-08
CY1117946T1 (el) 2017-05-17
IL200561A0 (en) 2010-05-17
ZA200905837B (en) 2012-01-25
US8183252B2 (en) 2012-05-22
TW200840580A (en) 2008-10-16
US20100292203A1 (en) 2010-11-18
AU2008219071B2 (en) 2013-03-28
AU2008219071A1 (en) 2008-08-28
PE20100731A1 (es) 2010-11-12
MY149183A (en) 2013-07-31
PE20081884A1 (es) 2008-12-27
US8691833B2 (en) 2014-04-08
IL200561A (en) 2015-03-31
ES2582367T3 (es) 2016-09-12
ME02528B (me) 2017-02-20
SI2097387T1 (sl) 2016-09-30
ECSP099597A (es) 2009-09-29
TWI355937B (en) 2012-01-11
CA2678958A1 (en) 2008-08-28
HUE029867T2 (en) 2017-04-28
KR20090114468A (ko) 2009-11-03
KR101612961B1 (ko) 2016-04-19
CO6220968A2 (es) 2010-11-19
EP2097387B1 (en) 2016-05-04
US20120276118A1 (en) 2012-11-01
RU2009135277A (ru) 2011-03-27
US7763609B2 (en) 2010-07-27
RU2496774C2 (ru) 2013-10-27
AR106237A2 (es) 2017-12-27
US8829036B2 (en) 2014-09-09
CN101715442B (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
LTC2178888I2 (lt) Proteazomos inhibitoriai
CY2020023I2 (el) Αναστολεiς βητα-λακταμασων
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
EP2305306A4 (en) NEURO INVASION INHIBITOR
BRPI0719204A2 (pt) Inibidores de hdac
BRPI0814797A2 (pt) Inibidores dna-pk
BRPI0918564A2 (pt) inibidores
ATE534010T1 (de) Zielfernrohr
BRPI1011267A2 (pt) inibidores de protease
DE602007004080D1 (de) Tintenstrahlaufnehmer
DK2066662T3 (da) Serinhydrolaseinhibitorer
DE602007000333D1 (de) Napfbefestigungsvorrichtung
DE112007003147A5 (de) Rohr-Biegevorrichtung
DE502007006319D1 (de) Staubabsaugadaptervorrichtung
EP2177529A4 (en) NEW SECRETASE HEMMER
BRPI0918966A2 (pt) inibidores de protease
DE102006045567A8 (de) Crimpstabilisierung
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
BRPI0813763A2 (pt) Inibidores da protease de cisteína
BRPI0919073A2 (pt) inibidores de protease
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
FI20065032A0 (fi) Menetelmä asbestialtistumiseen liittyvien keuhkosyöpien tunnistamiseksi

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: COREY STRICKLAND (US) , ELIZABETH M. SMITH (US) ,

B25G Requested change of headquarter approved

Owner name: COREY STRICKLAND (US) , ELIZABETH M. SMITH (US) ,

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements